Goldman Sachs’s Soleno Therapeutics SLNO Stock Holding History

Goldman Sachs’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,000	Closed	-$2.31M	–	6936
2025 Q4	$2.31M	Hold	50,000	–	–	﹤0.01%	4446
2025 Q3	$3.38M	Buy	+50,000	New	+$3.71M	﹤0.01%	4013

Goldman Sachs's SLNO Position: Q2 2026 in Review

Goldman Sachs sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 385,798 shares — an estimated $12.9M sold.

Goldman Sachs first reported a position in SLNO in Q3 2016 and held it in 20 quarters. The position peaked at $45.2M in Q1 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Goldman Sachs reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 385,798 Soleno Therapeutics shares in Q2 2026, an estimated $12.9M.
Goldman Sachs first reported a position in Soleno Therapeutics in Q3 2016 and held it in 20 quarters.
Goldman Sachs's Soleno Therapeutics position peaked at $45.2M in Q1 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.